Holen Sie sich die Stockscreener-App
25.59
1.47%
0.3699
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer (PFE) Sees Significant Options Activity in Latest Trading Session - GuruFocus
Jim Cramer on Pfizer: “I Think It Can Be Near a Breakout” - Insider Monkey
Is This the Best Value Stock to Buy While Markets Are Volatile? - The Motley Fool
Should FDA Approval of PADCEV-Keytruda Combo Shape the Outlook for Pfizer (PFE) Investors? - Yahoo Finance
Should FDA Approval of PADCEV Plus Keytruda Shift Pfizer's (PFE) Oncology Innovation Outlook? - simplywall.st
Which Is A Better Pick: Johnson & Johnson or Pfizer Stock? - Trefis
Guggenheim Raises Price Target for Pfizer (PFE) to $35 | PFE Sto - GuruFocus
Guggenheim Adjusts Price Target on Pfizer to $35 From $33, Maintains Buy Rating - MarketScreener
14 Stocks Jim Cramer Recently Shed Light On - Insider Monkey
MCC STEM students and employees visit Pfizer - Lowell Sun
A Look at Pfizer's Valuation Following FDA Approval of PADCEV Combination Therapy for Bladder Cancer - simplywall.st
2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon - Finviz
Pfizer Secures a Major Regulatory Win—How Will Its U.S. Drug Pricing Deal Shape 2026? - Smartkarma
Does Pfizer’s AI-Powered R&D Signal a New Opportunity for 2025? - Yahoo Finance
Pfizer, UnitedHealth, Viatris, Addus HomeCare, and Quest Stocks Trade Up, What You Need To Know - The Globe and Mail
Pfizer Inc. (PFE) Completes Significant Public Offering of Notes - GuruFocus
Pfizer completes $6 billion public notes offering across multiple maturities - Investing.com
Pfizer completes $6 billion public notes offering across multiple maturities By Investing.com - Investing.com India
Pfizer Sells $6 Billion of Notes - MarketScreener
Pfizer Completes $5 Billion Public Offering - TipRanks
Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch
Why Are Shares of Pfizer Up Today? - Benzinga
Pfizer, Astellas Say FDA Approves Padcev-Keytruda Combo in Bladder Cancer - MarketScreener
Pfizer (PFE) Gains FDA Approval for New Bladder Cancer Treatment - GuruFocus
mRNA flu shot shows better results than traditional vaccine in trial - upi.com
Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025 - ts2.tech
Pfizer's New mRNA Flu Vaccine Outperforms Traditional Shot Against Predominant StrainsPfizer (NYSE:PFE) - Benzinga
New Trial Shows Pfizer’s mRNA Flu Shot Beats Traditional Flu Vaccine - Citizen Tribune
Is Trending Stock Pfizer Inc. (PFE) a Buy Now? - Yahoo Finance
Medical Morphine Market Deep Research Report with Forecast - openPR.com
Necrotizing Fasciitis Market to Witness Remarkable Growth With - openPR.com
Amazon and Pfizer plunder $22bn on final approach to Thanksgiving - GlobalCapital
Pfizer (PFE) Agrees to $41.5 Million Settlement Over Drug Allega - GuruFocus
Is Pfizer's 6.9%-Yielding Dividend Still Safe? - Finviz
Pfizer scores a win for mRNA vaccines with influenza data - The Pharma Letter
Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too? - Barchart.com
HK-listed Hbm climbs to six-week high on licence deal with Pfizer - TradingView
Pfizer aims to seek oral obesity treatments worldwide following Metsera purchase – CEO - MSN
Pfizer: Is This Pharma Giant Finally A Bargain (NYSE:PFE) - Seeking Alpha
Pfizer, Tris Pharma Settle Texas ADHD Drug Case for $41.5 Million - MarketScreener
Pursuing the Next Breakthrough in Cancer Cachexia - Pfizer
Arbutus Reports Major Advances in HBV Candidate as Litigation Against Moderna, Pfizer Builds Toward Trial - MyChesCo
Pfizer, Tris Pharma Reach $41.5M Settlement in Texas ADHD Drug Fraud Suit - USA Herald
Pfizer To Pay $41.5M To Settle Adulterated ADHD Drug Claims - Law360
Pfizer in $41.5 million settlement with Texas over ADHD drug for children - WKZO
Pfizer, Tris Pharma Reach $41.5 Million Settlement With Texas Over Alleged Adulterated ADHD Medicine - MarketScreener
Pfizer (PFE) and Tris Pharma Settle ADHD Drug Lawsuit for $41.5M - GuruFocus
Pfizer, Tris Pharma To Pay Texas $41.5 Million in ADHD Drug Suit - news.bloomberglaw.com
Jefferies 25: Pfizer Still Hungry For Anti-Obesity Deals After Metsera - Citeline News & Insights
Pfizer resolves Texas lawsuit over adulterated ADHD drug in $41.5M settlement - Seeking Alpha
Vitiligo Market Analysis and Forecasts 2025-2035 Featuring Abbvie, Incyte, Amgen, Pfizer, Clinuvel Pharmaceuticals, TWi Biotech, and Arcutis BiotherapeuticsResearchAndMarkets.com - The AI Journal
Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025 - ts2.tech
Pfizer CEO on plans to bring down drug prices - Yahoo Finance
Pfizer in $41.5 million settlement with Texas over ADHD drug - MarketScreener
Pfizer intends to raise $5 billion to finance the deal with Metsera - AKM.RU
Ewing Sarcoma Market Research Report 2025-2035: Salarius, Eli Lilly, Pfizer, and BioAtla Lead by Driving Innovations in the Development of Novel Targeted Therapies - Yahoo Finance
HBM Holdings Partners with Pfizer for Antibody Discovery - TipRanks
Nona Biosciences and Pfizer Announce Strategic Research Collaboration to Accelerate Antibody Discovery - PR Newswire
Hbm Holdings' unit enters license agreement with Pfizer - MarketScreener
Pfizer to seek oral obesity drugs globally after Metsera deal- CEO - Investing.com
Pfizer at Jefferies Conference: Strategic Moves Amid Challenges By Investing.com - Investing.com Canada
1.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):